News & Updates
Filter by Specialty:
‘Triple-G’ obesity drug also targets NAFLD in phase II trial
In a subanalysis of a phase II trial on obesity, retatrutide, a triagonist of GIP*, GLP**, and glucagon receptors, also demonstrated multiple favourable signals for nonalcoholic fatty liver disease (NAFLD).
‘Triple-G’ obesity drug also targets NAFLD in phase II trial
11 Jul 2023
CV health tool effectively promotes discussions during routine follow-up in cancer survivors
A novel electronic health record (EHR) clinical decision support tool, otherwise called the AH-HA* tool, was effective in promoting cardiovascular health (CVH) discussions among cancer survivors during routine follow-up. This was the primary result of a clinic-randomized, hybrid effectiveness-implementation trial presented at ASCO 2023.
CV health tool effectively promotes discussions during routine follow-up in cancer survivors
06 Jul 2023
Once-weekly icodec affords greater blood sugar reduction than once-daily degludec in T2D
In the treatment of individuals with insulin-naïve type 2 diabetes (T2D), once-weekly icodec yields superior HbA1c reduction compared with once-daily degludec, according to the results of a phase IIIa trial.
